OncoMatch/Clinical Trials/NCT05919264
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Is NCT05919264 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for cancer.
Treatment: FOG-001 · mFOLFOX-6 · Nivolumab · Trifluridine/tipiracil · Bevacizumab — The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Tumor Agnostic
Hepatocellular Carcinoma
Prostate Cancer
Endometrial Cancer
Glioblastoma
Biomarker criteria
Required: APC loss-of-function mutation
Participants with tumors known to be negative for APC LoF mutations ... are not eligible
Required: CTNNB1 gain-of-function mutation
Participants with tumors known to be negative for ... CTNNB1 GoF mutations ... are not eligible
Disease stage
Required: Stage III, IV
Diagnosis of treatment-refractory advanced/metastatic solid tumor; locally advanced or metastatic non-MSI-H or non-dMMR CRC
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
Unstable/inadequate cardiac function excluded
Adequate organ and marrow function. Unstable/inadequate cardiac function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Honor Health · Scottsdale, Arizona
- Arizona Cancer Center at University of Arizona · Tucson, Arizona
- Stanford Cancer Institute, Stanford University · Palo Alto, California
- University of California San Francisco, Helen Diller Family Comprehensive Cancer Center · San Francisco, California
- Sarcoma Oncology Center · Santa Monica, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify